KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q3 2025 value amounting to $414.8 million.

  • Vertex Pharmaceuticals' Cost of Revenue rose 565.46% to $414.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 905.7%. This contributed to the annual value of $1.5 billion for FY2024, which is 2125.65% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Cost of Revenue stood at $414.8 million, which was up 565.46% from $407.5 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Cost of Revenue peaked at $423.4 million during Q4 2024, and registered a low of $192.3 million during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $308.6 million (2023), whereas its average is $313.8 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Cost of Revenue surged by 2989.76% in 2023 and then surged by 565.46% in 2025.
  • Vertex Pharmaceuticals' Cost of Revenue (Quarter) stood at $247.4 million in 2021, then increased by 14.51% to $283.3 million in 2022, then increased by 29.9% to $368.0 million in 2023, then increased by 15.05% to $423.4 million in 2024, then fell by 2.03% to $414.8 million in 2025.
  • Its Cost of Revenue was $414.8 million in Q3 2025, compared to $407.5 million in Q2 2025 and $363.0 million in Q1 2025.